meropenem/sulbactam / Generic mfg. - LARVOL DELTA

From Anorectal Surgery to Abdominal Lemierre Syndrome: Fusobacterium Necrophorum Bacteremia With Hepatic Abscesses (ACG 2026) - "Blood cultures grew Fusobacterium necrophorum resistant to clindamycin and susceptible to ampicillin-sulbactam, meropenem, and metronidazole. Recognition that pylephlebitis is a clinical pathophysiologic diagnosis is essential to ensure prompt anaerobic directed therapy, source control, and prolonged treatment duration. Figure: CT abdomen pelvis with IV contrast revealed multiple hepatic abscesses; this image highlights the largest lesion in segment VI measuring 2.5 Ã 1.8 cm."

Surgery • Acute Kidney Injury • Cardiovascular • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hepatology • Immunology • Infectious Disease • Nephrology • Pulmonary Disease • Renal Disease • Thrombocytopenia • Thrombosis

Surveillance of antimicrobial resistance in neonatal intensive care unit of Alexandria University Children's Hospital. (PubMed, Sci Rep) - "It was maximum (94-80%) for Cefotaxime, Piperacillin, Amoxicillin/Clavulanic acid, and ceftriaxone. It varied between 60 and 80% for Piperacillin/Tazobactam, Imipenem, Ceftazidime, Cefoperazone/Sulbactam, Meropenem, Ampicillin/Sulbactam, and Ciprofloxacin...K. pneumoniae was the predominant pathogen in both EOS and LOS in our study, similar to other developing countries, and is totally different from developed countries."

Journal • Critical care • Infectious Disease • Pneumonia • Septic Shock

Emerging hypervirulent and extensively drug-resistant Klebsiella pneumoniae with potent biofilm formation as a new clinical challenge. (PubMed, Mol Biol Rep) - "Antimicrobial susceptibility and colistin broth disk elution were also conducted...Regarding antibiotic susceptibility, cefotaxime showed the weakest effect, with 100% resistance, followed by cefoxitin, ampicillin-sulbactam, meropenem, ceftazidime, and cefepime, each of which demonstrated a 90% resistance rate. Tetracycline and gentamicin were the most effective antibiotics, with susceptibility rates of 60% and 50%, respectively...Moreover, 80% of presumptive hvKp isolates demonstrated biofilm formation capacity, with 20% showing strong biofilm formation. The emergence of biofilm-producing and XDR strains underscores the need for enhanced surveillance and effective infection control measures."

Journal • Infectious Disease • Pneumonia

Microbiological and inflammatory profiles in diabetic foot infection: A severity-stratified analysis. (PubMed, Medicine (Baltimore)) - "Gram-positive (G+) isolates exhibited high susceptibility to gentamicin, vancomycin, oxacillin, and linezolid, with no intergroup differences...Gram-negative (G-) bacteria showed consistent susceptibility to ampicillin, levofloxacin, ceftazidime, cefoperazone-sulbactam, and meropenem across severity groups...Empirical antibiotic treatment should be guided by local antimicrobial susceptibility patterns. The strong correlation of HNL and PCT with infection severity suggests their potential value in clinical assessment and management."

Biomarker • Journal • Retrospective data • Endocrine Disorders • Infectious Disease • Pneumonia • CRP

MULTIDRUG-RESISTANT ACINETOBACTER SPP. BLOODSTREAM INFECTIONS IN HEMATOLOGIC PATIENTS: CLINICAL CHARACTERISTICS, GENOMIC FEATURES, AND ERAVACYCLINE-BASED COMBINATION THERAPY (EHA 2026) - "Checkerboard assays evaluated the in vitro activity of eravacycline combined with sulbactam, meropenem, cefoperazone-sulbactam, polymyxin B, and levofloxacin. Summary/Conclusion Eravacycline exhibited strong intrinsic activity and favorable synergy with sulbactam, supporting its potential role in treating MDR Acinetobacter spp. infections in this high-risk population."

Clinical • Combination therapy • Hematological Disorders • Infectious Disease • Neutropenia

mSTARS: mHealth-supported Skills Training for Alcohol-Related Suicidality (clinicaltrials.gov) - P=N/A | N=10 | Enrolling by invitation | Sponsor: Duke University | Trial completion date: Feb 2028 ➔ Aug 2026 | Trial primary completion date: Feb 2028 ➔ Aug 2026

Trial completion date • Trial primary completion date

Multidrug-resistant Acinetobacter spp. bloodstream infections in hematologic patients: clinical characteristics, genomic features, and eravacycline-based combination therapy. (PubMed, BMC Infect Dis) - "Eravacycline exhibited strong in vitro activity and favorable synergy with sulbactam, supporting its potential role in treating MDR Acinetobacter spp. infections in this high-risk population."

Journal • Hematological Disorders • Infectious Disease • Neutropenia

Case report: Delayed onset rash, delirium, and cross allergic reactions caused by sequential administration of cefoperazone sulbactam, meropenem, and piperacillin tazobactam. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "This article reports a case of a 91-year-old male patient who, due to a pulmonary infection and hip replacement surgery, successively used four β-lactam antibacterial drugs: ceftriaxone, cefoperazone-sulbactam, meropenem, and piperacillin-tazobactam. This case indicates that elderly patients require strengthened individualized medication monitoring and high vigilance for cross-allergic reactions caused by homologous side-chain structures of β-lactam drugs. Full-process pharmaceutical supervision is key to ensuring the safe use of antibacterial drugs in elderly patients."

Journal • Allergy • CNS Disorders • Geriatric Disorders • Immunology • Infectious Disease • Orthopedics • Respiratory Diseases

RIV-TARGET: Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex (clinicaltrials.gov) - P3 | N=248 | Recruiting | Sponsor: BioVersys SAS | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Pneumonia • Respiratory Diseases

NALFURAFINE FOR REFRACTORY UREMIC AND CHOLESTATIC PRURITUS IN A HEMODIALYSIS PATIENT: A CASE REPORT (ISN-WCN 2026) - "During her course, she experienced recurrent spontaneous bacterial peritonitis (pathogen: vancomycin-resistant Enterococcus faecium) necessitating multiple courses of broad-spectrum antibiotics (including cefoperazone-sulbactam, meropenem, daptomycin, linezolid)...Initially suspected as a drug allergy, all potential culprit medications were discontinued, and prednisone was administered...Despite trials of various standard therapies including antihistamines, intensified hemodialysis with hemoperfusion, gabapentin, ursodeoxycholic acid, sertraline, topical tacrolimus ointment, and achieving targets for phosphate and parathyroid hormone control, the generalized pruritus remained refractory...This outcome underscores its mechanistic advantage and potential therapeutic value in challenging clinical scenarios involving mixed-origin pruritus.Conclusion In conclusion, nalfurafine presents a promising therapeutic option for refractory pruritus of mixed uremic and cholestatic..."

Case report • Clinical • Chronic Kidney Disease • Dermatology • Fibrosis • Hepatology • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis • Liver Failure • Nephrology • Pruritus • Renal Disease • Urticaria

Antimicrobial activity of sulbactam-durlobactam against Acinetobacter baumannii-calcoaceticus complex strains causing non-respiratory and non-bloodstream infections from the United States (2023-2025). (PubMed, Microbiol Spectr) - "This study aims to evaluate the in vitro activity of sulbactam-durlobactam and comparator antibiotics, including meropenem and cefiderocol against A. baumannii-calcoaceticus complex isolates from non-respiratory and non-bloodstream sources...Minocycline susceptibility was 69.1%, while tigecycline and eravacycline MICs50/90 were 1/4 and 0.5/1 mg/L, respectively...The results are important because they can inform clinicians on the susceptibility profiles of A. baumannii from a variety of infection sources, not just lung and bloodstream. As new antibiotics come onto the market, it is important to continuously assess resistance patterns to inform patient and system-wide health decisions."

Journal • Infectious Disease • Nephrology • Pneumonia • Respiratory Diseases

MULTIDRUG-RESISTANT ACINETOBACTER SPP. BLOODSTREAM INFECTIONS IN HEMATOLOGIC PATIENTS: CLINICAL CHARACTERISTICS, GENOMIC FEATURES, AND ERAVACYCLINE-BASED COMBINATION THERAPY (EBMT 2026) - "Checkerboard assays evaluated the in vitro activity of eravacycline combined with sulbactam, meropenem, cefoperazone–sulbactam, polymyxin B, and levofloxacin. This study provides comprehensive clinical, microbiological, and genomic insights into MDR Acinetobacter spp. BSI in hematologic patients. The high mortality associated with MDR-BSI underscores the urgent need for effective therapeutic strategies."

Clinical • Combination therapy • Hematological Disorders • Infectious Disease • Neutropenia

MULTIDRUG-RESISTANT ACINETOBACTER SPP. BLOODSTREAM INFECTIONS IN HEMATOLOGIC PATIENTS: CLINICAL CHARACTERISTICS, GENOMIC FEATURES, AND ERAVACYCLINE-BASED COMBINATION THERAPY (EBMT 2026) - "Checkerboard assays evaluated the in vitro activity of eravacycline combined with sulbactam, meropenem, cefoperazone–sulbactam, polymyxin B, and levofloxacin. This study provides comprehensive clinical, microbiological, and genomic insights into MDR Acinetobacter spp. BSI in hematologic patients. The high mortality associated with MDR-BSI underscores the urgent need for effective therapeutic strategies."

Clinical • Combination therapy • Hematological Disorders • Infectious Disease • Neutropenia

mSTARS: mHealth-supported Skills Training for Alcohol-Related Suicidality (clinicaltrials.gov) - P=N/A | N=10 | Enrolling by invitation | Sponsor: Duke University | Not yet recruiting ➔ Enrolling by invitation | Trial completion date: Apr 2026 ➔ Feb 2028 | Trial primary completion date: Apr 2026 ➔ Feb 2028

Enrollment open • Trial completion date • Trial primary completion date

"In vitro evaluation of sulbactam combination therapies for Acinetobacter baumannii". (PubMed, Indian J Med Microbiol) - "Combining sulbactam with β-lactams, particularly cefepime, significantly reduced sulbactam MICs. However, the β-lactam MICs themselves remained largely within not-susceptible ranges, highlighting that the observed benefit was confined primarily to sulbactam rather than the companion β-lactams. These findings supported further clinical studies of high-dose sulbactam-β-lactam combinations to optimize the pharmacodynamic efficacy of sulbactam against CRAB strains with elevated MICs."

Journal • Preclinical • Infectious Disease • Pneumonia • Respiratory Diseases

Comparative effectiveness of two antimicrobial regimens for the treatment of pan-drug-resistant Acinetobacter baumannii infections: results from the DESPAIR study. (PubMed, Antimicrob Agents Chemother) - "Salvage therapy and treatment discontinuation due to toxicity were more frequent in patients treated with regimen B. In multivariable analysis, regimen B was independently associated with 28-day mortality before (hazard ratio [HR]: 2.53; 95% CI: 1.08-5.94) but not after propensity matching (HR: 2.64; 95% CI: [0.99-7.02]). Treatment with colistin, ampicillin-sulbactam, and meropenem against severe PDR-AB infections was associated with favorable outcomes compared to colistin, ampicillin-sulbactam, and tigecycline."

HEOR • Journal • Infectious Disease • Pneumonia • Respiratory Diseases

RIV-TARGET: Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex (clinicaltrials.gov) - P3 | N=248 | Not yet recruiting | Sponsor: BioVersys SAS

New P3 trial • Infectious Disease • Pneumonia • Respiratory Diseases

mSTARS: mHealth-supported Skills Training for Alcohol-Related Suicidality (clinicaltrials.gov) - P=N/A | N=10 | Not yet recruiting | Sponsor: Duke University | Trial completion date: Dec 2025 ➔ Apr 2026 | Trial primary completion date: Dec 2025 ➔ Apr 2026

Trial completion date • Trial primary completion date

Traceability and Characteristic Investigation of Burkholderia Gladioli Bloodstream Infection in Patients with Hematologic Malignancies (ASH 2023) - "Antibiotic susceptibility tests revealed that the clinical strains were susceptible to cefazoxime, ciprofloxacin, levofloxacin, trimethoprim/sulfamethoxazole, cefalexin, cefoperazone/sulbactam, meropenem, imipenem, piperacillin/tazobactam, amikacin, tobramycin, minocycline hydrochloride, tigecycline and resistant to polymyxinB, ampicillin, cefazolin, cefuroxime, aztreonam, and cefoxitin. Foodborne B. gladioli strains in this study exhibited low toxicity and high thermal stability and caused opportunistic bloodstream infections of hematologic malignant patients in immunodeficient states, which deserves our attention. Its special biological characteristic might be attributed to whole and partial loss of toxigenic gene clusters. Clinical B gladioli strains are resistant to polymyxinB, but the standard B gladioli strain and lethal B gladioli strain are susceptible to it, indicating acquired resistance during colonization and empirical antibiotic therapy."

Clinical • Cystic Fibrosis • Febrile Neutropenia • Genetic Disorders • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Neutropenia • Oncology • Primary Immunodeficiency • Respiratory Diseases

Effect of Meropenem, Sulbactam, and Colistin Combinations on Resistance Gene Expression in Multidrug-Resistant A. baumannii Clinical Isolates from Panama. (PubMed, Antibiotics (Basel)) - "Therefore, this study offers a new perspective on how rational combinations of clinically used antibiotics have the potential to modulate gene expression and contribute to the control of MDR strains, indicating that high-dose combination therapy with sulbactam and colistin could offer improved efficacy in treating multidrug resistant Acinetobacter baumannii infections."

Journal • Infectious Disease

Synergistic activity of meropenem and sulbactam against carbapenem-resistant Acinetobacter baumannii. (PubMed, Indian J Pharmacol) - "In the current checkerboard assay, we observed potential synergistic activity between meropenem and sulbactam against CRAB isolates which indicates that this combination can be an appealing strategy in the treatment of nosocomial infections caused by CRAB isolates."

Journal • Infectious Disease

mSTARS: mHealth-supported Skills Training for Alcohol-Related Suicidality Phase 3 (clinicaltrials.gov) - P=N/A | N=35 | Not yet recruiting | Sponsor: Duke University | Trial completion date: Aug 2027 ➔ Dec 2027

Trial completion date

mSTARS: mHealth-supported Skills Training for Alcohol-Related Suicidality (clinicaltrials.gov) - P=N/A | N=10 | Not yet recruiting | Sponsor: Duke University | Trial completion date: Sep 2025 ➔ Dec 2025 | Trial primary completion date: Sep 2025 ➔ Dec 2025

Trial completion date • Trial primary completion date

Clinical and genomic insights into Acinetobacter parvus: A rare pathogen with low antibiotic resistance and potential clinical implications. (PubMed, J Microbiol Immunol Infect) - "This study sheds light on the clinical potential of Acinetobacter parvus, particularly in immunocompromised patients. While its low resistance profile allows for effective treatment, its ability to cause infections warrants further attention."

Journal • Infectious Disease

Real-world efficacy and safety of cefepime for pediatric community-acquired pneumonia: a propensity score-matched study. (PubMed, Front Cell Infect Microbiol) - "This study aimed to evaluate the real-world clinical efficacy and safety of cefepime in treating pediatric community-acquired pneumonia (CAP), comparing it with other broad-spectrum antibiotics, including cefoperazone-sulbactam and meropenem, using a propensity score-matched design. These findings support cefepime as a viable empiric therapy option, particularly in settings with limited microbiological diagnostics. Further studies are needed to confirm these results and optimize dosing strategies for pediatric populations."

Journal • Real-world evidence • Retrospective data • Infectious Disease • Pediatrics • Pneumonia • Respiratory Diseases